Abstract
Chapters 2–4 of this book describe in details the mechanisms of localization for tumor-seeking agents. In this chapter we will consider only the most important radiopharmaceuticals currently used as tumor-seeking agents in clinical practice, and we will briefly summarize the PET modalities of PET imaging in oncology. We will also briefly discuss the main features of PET imaging as compared to conventional morphologic imaging (CT and MRI), in terms of biological meaning of the diagnostic information. Finally, a series of teaching cases will illustrate how PET-based imaging is currently employed for each type of cancer in the scenario of the most common clinical applications, e.g., staging, restaging, evaluation of response to therapy, and others.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Som P, Atkins HL, Bandoypadhyay D, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med. 1980;21:670–5.
Podo F. Tumour phospholipid metabolism. NMR Biomed. 1999;12:413–39.
Kwee SA, Coel MN, Ly BH, et al. 18F-Choline PET/CT imaging of RECIST measurable lesions in hormone refractory prostate cancer. Ann Nucl Med. 2009;23:541–8.
Luboldt W, Küfer R, Blumstein N, et al. Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases. Radiology. 2008;249:1017–25.
Huang Z, Zuo C, Guan Y, et al. Misdiagnoses of 11C-choline combined with 18F-FDG PET imaging in brain tumours. Nucl Med Commun. 2008;29:354–8.
Hara T, Kosaka N, Shinoura N, et al. PET imaging of brain tumor with [methyl-11C]choline. J Nucl Med. 1997;38:842–7.
Khan N, Oriuchi N, Ninomiya H, et al. Positron emission tomographic imaging with 11C-choline in differential diagnosis of head and neck tumors: comparison with 18F-FDG PET. Ann Nucl Med. 2004;18:409–17.
Salem N, Kuang Y, Wang F, et al. PET imaging of hepatocellular carcinoma with 2-deoxy-2[18F]fluoro-D-glucose, 6-deoxy-6[18F]fluoro-D-glucose, [1-11C]-acetate and [N-methyl-11C]-choline. Q J Nucl Med Mol Imaging. 2009;53:144–56.
Beheshti M, Langsteger W. PET imaging of prostate cancer using radiolabeled choline. PET Clin. 2009;4:173–84.
Pascali G, D’Antonio L, Bovone P, et al. Optimization of automated large-scale production of [18F]fluoroethylcholine for PET prostate cancer imaging. Nucl Med Biol. 2009;36:569–74.
Youland RS, Kitange GJ, Peterson TE, et al. The role of LAT1 in 18F-DOPA uptake in malignant gliomas. J Neuro-Oncol. 2013;111:11–8.
Gazdar AF, Helman LJ, Israel MA, et al. Expression of neuroendocrine cell markers L-dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res. 1988;48:4078–82.
F T, Ehmer J, Piroth MD, et al. The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with glioblastoma. Phys Med Biol. 2009;54:5525–39.
Stadlbauer A, Prante O, Nimsky C, et al. Metabolic imaging of cerebral gliomas: spatial correlation of changes in O-(2-18F-fluoroethyl)-L-tyrosine PET and proton magnetic resonance spectroscopic imaging. J Nucl Med. 2008;49:721–9.
Stadlbauer A, Pölking E, Prante O, et al. Detection of tumour invasion into the pyramidal tract in glioma patients with sensorimotor deficits by correlation of 18F-fluoroethyl-L-tyrosine PET and magnetic resonance diffusion tensor imaging. Acta Neurochir. 2009;151:1061–9.
Sharma MR, Maitland ML, Ratain MJ. RECIST: no longer the sharpest tool in the oncology clinical trials toolbox. Cancer Res. 2012;72:5145–9.
Ruiz C, Lenkiewicz E, Evers L, et al. Advancing a clinically relevant perspective of the clonal nature of cancer. Proc Natl Acad Sci U S A. 2011;108:12054–9.
https://www.nccn.org/professionals/physician_gls/f_guidelines.asp
Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.
Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. http://www.snm.org/guidelines
Further Reading
Hara T, et al. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998;39:990–6.
Hogerle S, et al. Whole-body 18F-DOPA PET for detection of gastrointestinal carcinoid tumors. Radiology. 2001;220:373–80.
Popperl G, et al. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med. 2006;47:393–403.
Shreve PD, et al. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19:61–7.
Wahl RL, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(suppl 1):122S–50S.
Zhuang H, et al. Dual time point 18F-FDG PET imaging for differentiating malignant form inflammatory processes. J Nucl Med. 2001;42:1412–7.
Links to Interesting Websites
www.eanm.org. Accessed 16 Oct 2017.
www.snmmi.org. Accessed 14 Oct 2017.
www.nccn.org. Accessed 10 Oct 2017.
www.esmo.org. Accessed 14 Oct 2017.
www.ncbi.nlm.nih.gov/pubmed/. Accessed 26 Oct 2017.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Evangelista, L. et al. (2019). Teaching Cases in Nuclear Medicine: Oncological Applications. In: Volterrani, D., Erba, P.A., Carrió, I., Strauss, H.W., Mariani, G. (eds) Nuclear Medicine Textbook. Springer, Cham. https://doi.org/10.1007/978-3-319-95564-3_48
Download citation
DOI: https://doi.org/10.1007/978-3-319-95564-3_48
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-95563-6
Online ISBN: 978-3-319-95564-3
eBook Packages: MedicineMedicine (R0)